Tracker

ETF universe handoff

Opening ETF evidence benchSynchronizing prices, risk metrics, holdings coverage, and source lineage

Company context

Johnson & Johnson

NYSE:JNJ

Pharmaceuticals: Major · benchmarked against Pharmaceuticals: Major inside the XLV constituent company universe.

Active tabFinancial reports

Current readMixed

Last close249.76

1M return-3.69%

Open symbol page Watchlist context

OverviewVerdict, thesis map, and valuation setup.FundamentalsDrivers, trajectory, and business quality.Financial reportsStatement tables, sorting, filtering, and acceleration.Ex-ante forecastTarget price, dividend yield, and total return by horizon.FactorsCompany factor exposure, rank, and universe context.Market viewMomentum, catalysts, charts, and symbol packet.AttributionLarge-move causes, residuals, and research backlog.OwnershipSEC 13F holder flow, crowding, and manager changes.PeersPeer heatmap and closest comparables.

Tab scope

Raw financial statements

Financial reports

Source and lookbackStored financial report rows12 report snapshots; latest report Jul 16, 8:20 PM GMT+8.

Sample and caveat28 reported metrics across 4 sections.Use this tab for its stated job; heavier model packets stay on their own tabs.

Traditional statement tables

Financial reports

12 reports · latest Jul 16, 8:20 PM GMT+8

Distinct report rows12

Sections4

Metrics28

Coverage100%

CompanyJohnson & Johnson

Overview scoring

Fundamental overview

51/100 blended · 99/100 confidence · benchmark Closest peers

Blended fundamental score: Earnings 72/100; Cash flow 41/100; Balance sheet 44/100; Valuation 28/100.

Broad comparison

Cohort scorecard

Coverage-adjusted score with thinner cohorts automatically down-weighted

Cohort scorecard: Closest peers 49/100; Pharmaceuticals: Major 50/100; Health Technology 54/100; XLV constituent company universe 52/100.

Selected company rank

Rank and percentile

Confidence-adjusted standing inside each cohort

Rank and percentile: Closest peers #11 of 13; Pharmaceuticals: Major #10 of 12; Health Technology #13 of 41; XLV constituent company universe #23 of 59.

Section scoring matrix

Earnings, cash flow, balance sheet, and valuation

Heatmap score by cohort and statement section

Section scoring matrix: Closest peers Earnings 71/100; Cash flow 37/100; Balance sheet 44/100; Valuation 27/100.

Sort byFilter metrics

Specialist report review

Quant, PM, and risk-manager reads

Deterministic review lanes from stored report metrics

Quant review

Favorable acceleration13/24

P/E TTM has the largest second-order move at -36.77%. 13 metrics are accelerating favorably and 11 are decelerating.

Fundamental PM review

Growth and cash quality2/5

EPS TTM is 8.63 with -0.24% latest change. The PM lane checks revenue, EPS, cash flow, and margin confirmation together.

Risk manager review

Risk controls need review3 watch items

Debt / Equity is 0.68 with +11.95% latest change. The risk lane checks leverage, liquidity, and cash-yield deterioration.

Indexed report history

Financial report trend chart

First visible report = 100

Financial report trend chart: Total revenue 94.2B; Revenue quarter 25.3B; Revenue next quarter 25.3B; Operating income TTM 26.2B.

Second order change

Acceleration chart

Favorable acceleration means the latest move improved versus the prior move

Acceleration chart: Total revenue -2.23%; Revenue quarter +7.22%; Operating income TTM +0.21%; Operating margin +0.20%.

PM / risk lens

Risk and quality radar

Directional score from change and acceleration

Risk and quality radar: Growth 60/100; Cash 25/100; Quality 38/100; Balance 45/100; Valuation 38/100.

Earnings

Metric trend table

10 of 10 metrics shown

Metric	Latest	Change	Acceleration	Trend	Samples
Total revenueRevenue	94.2B	-0.01%-11M	-2.23%-2.1B	decelerating	11
Revenue quarterRevenue	25.3B	+5.19%+1.2B	+7.22%+1.7B	accelerating	12
Revenue next quarterRevenue	25.3B	+1.44%+358.3M	Need 3 reportsNeed 3 reports	improving	2
Operating income TTMEarnings	26.2B	+1.29%+335M	+0.21%+57M	improving	12
Operating marginProfitability	+27.86%	+1.29%+0.36 pts	+0.20%+0.06 pts	improving	12
EPS TTMEarnings	8.63	-0.24%-0.02	+21.46%+2.38	accelerating	9
EPS next quarterEarnings	3.05	+7.32%+0.21	Need 3 reportsNeed 3 reports	improving	2
Gross marginQuality	+75.08%	+10.47%+7.12 pts	+10.48%+7.13 pts	accelerating	12
Net marginQuality	+21.48%	-1.62%-0.35 pts	+21.66%+6.27 pts	accelerating	12
Gross-to-net conversionQuality	+28.61%	-10.94%-3.52 pts	+12.32%+6.23 pts	accelerating	12

Historical statement rows

Earnings report history

12 dated rows

Snapshot date	Total revenue	Revenue quarter	Revenue next quarter	Operating income TTM	Operating margin	EPS TTM	EPS next quarter	Gross margin	Net margin	Gross-to-net conversion
Oct 2, 2023	95.3B	21.3B	—	25.4B	+26.68%	—	—	+68.02%	+13.53%	+19.90%
Jan 2, 2024	93B	21.4B	—	23.9B	+25.66%	—	—	+67.94%	+14.53%	+21.39%
Apr 1, 2024	89.7B	21.4B	—	23B	+25.66%	—	—	+68.49%	+18.78%	+27.42%
Jul 1, 2024	86.6B	22.4B	—	22.5B	+25.94%	6.92	—	+68.75%	+18.92%	+27.53%
Oct 7, 2024	87.7B	22.5B	—	21.6B	+24.60%	6.05	—	+68.67%	+16.84%	+24.52%
Jan 6, 2025	88.8B	22.5B	—	20.9B	+23.52%	5.80	—	+68.71%	+15.84%	+23.05%
Apr 7, 2025	89.3B	21.9B	—	21.3B	+23.83%	9.00	—	+68.24%	+24.41%	+35.78%
Jul 7, 2025	90.6B	23.7B	—	21.8B	+24.02%	9.35	—	+68.12%	+25.01%	+36.71%
Oct 6, 2025	92.1B	24B	—	23.8B	+25.79%	10.36	—	+68.27%	+27.26%	+39.93%
Jan 5, 2026	94.2B	24.6B	—	25.6B	+27.21%	11.05	—	+67.97%	+28.46%	+41.87%
Apr 24, 2026	94.2B	24.1B	25B	25.9B	+27.51%	8.65	2.84	+67.96%	+21.83%	+32.13%
Jul 16, 2026	94.2B	25.3B	25.3B	26.2B	+27.86%	8.63	3.05	+75.08%	+21.48%	+28.61%